Quercis Pharma AG is a private Swiss biotech company advancing a novel antithrombotic in multiple indications: the lead program is prevention of Venous Thrombosis Embolism in advanced cancer patients (phase III) followed by clinical trials in Sickle Cell Disease (phase II) and Covid-19 (phase II).

Products, services, technology

Quercis' drug candidate is a an isoquercetin-based formulation that prevents platelet activation and initiation of the thrombotic cascade without increasing the risk of bleeding.

Cooperation possibilities

Quercis is open for licensing partnerships.

Facts & figures
  • Type of organization
    Private company
  • Year of foundation
  • Number of employees in Switzerland
Key business

You may also be interested in